ライフサイエンスコーパス: pluripotent cell

1 we show that this instability only occurs in pluripotent cells.

2 ed in undifferentiated hPSCs compared to non-pluripotent cells.

3 ns of the endogenous Oct4 distal enhancer in pluripotent cells.

4 to enhance reprogramming of fibroblasts into pluripotent cells.

5 fic genome structures and gene expression in pluripotent cells.

6 ted, contractile fibers from mouse and human pluripotent cells.

7 omatic cells, resulting in the generation of pluripotent cells.

8 germ cells given their similarities to naive pluripotent cells.

9 ating that they were fully reprogrammed into pluripotent cells.

10 growth factor GDF9 can reprogram hADFs into pluripotent cells.

11 and effectiveness of cell differentiation of pluripotent cells.

12 ning the culture requirements of naive human pluripotent cells.

13 ry meristems can be traced back to groups of pluripotent cells.

14 es that have bivalent chromatin structure in pluripotent cells.

15 ng loci were bound by Mediator or cohesin in pluripotent cells.

16 lation, suggesting it is a pivotal marker of pluripotent cells.

17 engraftment of blood progenitors from human pluripotent cells.

18 ry program at the G(1)/S-phase transition in pluripotent cells.

19 cations at the Oct4 locus in fibroblasts and pluripotent cells.

20 tive way to induce CPCs from mouse and human pluripotent cells.

21 is the key feature of murine totipotent and pluripotent cells.

22 lture can also induce abnormalities in these pluripotent cells.

23 sands of somatic regulatory sequences within pluripotent cells.

24 ith endoderm promotes induction of CPCs from pluripotent cells.

25 aining the differentiation responsiveness of pluripotent cells.

26 erences between in vitro and ex vivo primate pluripotent cells.

27 ion between embryonic stem cells and induced pluripotent cells.

28 tified proteins and phosphorylation sites in pluripotent cells.

29 n the formation of teratomas by transplanted pluripotent cells.

30 C/C substrates are also present during G1 of pluripotent cells.

31 on in a broad range of cell types, including pluripotent cells.

32 lls and in epigenetic remodeling of germ and pluripotent cells.

33 cle structure and transcriptional network of pluripotent cells.

34 feeders for both autologous and heterologous pluripotent cells.

35 ibody repertoires and the differentiation of pluripotent cells.

36 tional regulator of differentiation in these pluripotent cells.

37 y novel peptides that bind to the surface of pluripotent cells.

38 via diploid aggregation, unique to bona fide pluripotent cells.

39 tained the matrix signal for differentiating pluripotent cells.

40 ns methylated differently in fibroblasts and pluripotent cells.

41 genetic differences between naive and primed pluripotent cells.

42 reater in ESC-differentiated neurons than in pluripotent cells.

43 in establishing neural lineage commitment in pluripotent cells.

44 the genetic regulation of gene expression in pluripotent cells.

45 required to produce cellular diversity from pluripotent cells.

46 may contribute to its biological activity in pluripotent cells.

47 ay to drive mesendodermal differentiation of pluripotent cells.

48 ariants affecting the transcriptome of human pluripotent cells.

49 dynamics during lineage commitment of human pluripotent cells.

50 ether are sufficient to generate retina from pluripotent cells.

51 he role of the transcription factor Foxd3 in pluripotent cells.

52 alance between transcriptional programmes in pluripotent cells.

53 ction in gene expression regulation in mouse pluripotent cells.

54 ure cell types of all three germ layers from pluripotent cells.

55 in the transcriptional regulatory network of pluripotent cells.

56 How is end protection achieved in pluripotent cells?

57 Lack of MEG3 expression in human induced pluripotent cells altered the chromatin distribution of

58 The terms pluripotent cell and stem cell are often used interchang

59 tand the role of this molecular pathway in a pluripotent cell and the impact of CSB mutation during h

60 of up to 100 cardiomyocytes for every input pluripotent cell and was effective in 11 hiPSC lines tes

61 w that Jarid2/Jumonji, a protein enriched in pluripotent cells and a founding member of the Jumonji C

62 Genome-wide profiling of pluripotent cells and differentiated cells suggests glob

63 is sufficient to drive iXEN cells from mouse pluripotent cells and differentiated neural cells.

64 Tet1 and Tet2 are highly expressed in mouse pluripotent cells and downregulated to different extents

65 chanism of histone methylation regulation in pluripotent cells and during early cell-fate transitions

66 f the mutated cell; earlier mutations target pluripotent cells and generate more widespread disease a

67 CNA proteins are expressed across eukarya in pluripotent cells and have conserved functions in fertil

68 mportance of post-transcriptional control in pluripotent cells and identify miRNAs and RNA-binding pr

69 HH signaling keeps XCI in check in pluripotent cells and is transduced by GLI transcription

70 ine de novo synthesis pathway in cell lines, pluripotent cells and primary human T cells.

71 ning gene 9 (Sox9) is expressed initially in pluripotent cells and subsequently in ectodermal, endode

72 enriched at polycomb and stem cell genes in pluripotent cells and that TRF1 abrogation results in in

73 ty to detect chromosomal gains and losses in pluripotent cells and their derivatives, as well as meio

74 n of haemangioblasts and cardiomyocytes from pluripotent cells, and for the origins of stem cells in

75 limiting requirement for differentiation of pluripotent cells, and that experimental suppression of

76 oportion of the protein kinase complement of pluripotent cells, and there is accumulating evidence th

77 The generation of patient-derived pluripotent cells applicable to disease modelling, drug

78 Finally, while macroH2A dKO-induced pluripotent cells are able to differentiate properly in

79 ow intracellular signaling pathways in human pluripotent cells are coordinated and how they maintain

80 ylation during reprogramming, while ESC-like pluripotent cells are distinguished by extension of deme

81 Over 12-14 d, pluripotent cells are efficiently specified along the ne

82 When pluripotent cells are exposed to a uniform culture envir

83 t silence retrotransposons in germ cells and pluripotent cells are important for limiting the accumul

84 fferentiation, which could shed light on why pluripotent cells are only receptive to differentiation

85 In mice, pluripotent cells are thought to derive from cells burie

86 the major binding partner of Id proteins in pluripotent cells as the basic helix-loop-helix (bHLH) t

87 XD3 modulates the developmental potential of pluripotent cells as they differentiate.

88 MSC (C3H10T1/2 pluripotent cells as well as mouse marrow-derived MSC) w

89 use epiblast stem cells, which correspond to pluripotent cells at a late post-implantation stage of e

90 of the distal TSS is highly active in naive pluripotent cells, autonomously reports Tet1 expression

91 complex cell and environmental regulation of pluripotent cell behaviour, and suggest simple determini

92 The recent advent of pluripotent cell biology has opened new avenues for neur

93 loci indicates that a subset is expressed in pluripotent cells but not in diverse fetal and adult tis

94 Such marks have been identified in pluripotent cells, but it is unknown how such marks occu

95 iated hPS cells, had little or no binding on pluripotent cells, but preferential binding to certain e

96 nes the subtype of cancer arising from these pluripotent cells by altering their fate.

97 henomenon of somatic cell reprogramming into pluripotent cells by exposure to sublethal stimuli, whic

98 he strictest of all developmental assays for pluripotent cells by generating completely iPSC-derived

99 Secondary growth is initiated from groups of pluripotent cells, called meristems, which are establish

100 The acquisition of pluripotent cells can be achieved by combined overexpres

101 Transitory pluripotent cells can be captured at different time poin

102 Pluripotent cells can be captured via the archetypal der

103 Pluripotent cells can be derived from various types of s

104 nscriptionally distinct teratomas from which pluripotent cells can be recovered.

105 reporter-based studies of gene expression in pluripotent cells can be significantly influenced by the

106 However, much work remains to be done before pluripotent cells can be used for preclinical and clinic

107 The advantages that these pluripotent cells can offer in comparison to other sourc

108 tracellular matrix populated with autologous pluripotent cells can result in de-novo organogenesis, b

109 These induced pluripotent cells can subsequently be differentiated int

110 fined culture environments the properties of pluripotent cells change in an orderly sequence.

111 We find that in pluripotent cells, clustered CpG-islands at genes predic

112 MEK1 was required to make Xenopus pluripotent cells competent to respond to all cell fate

113 hether endothelial cells differentiated from pluripotent cells could serve as surrogates to test emer

114 We also apply this system to pluripotent cell culture and demonstrate that it faithfu

115 er with image analysis of single embryos and pluripotent cell culture, we have found that Notch is ac

116 The greatest potential for induced pluripotent cells derived from affected individuals is l

117 Epiblast stem cells (EpiSCs) are pluripotent cells derived from post-implantation late ep

118 Induced pluripotent cell-derived motoneurons (iPSCMNs) are sough

119 between GBA and CTSB and GBA p.N370S induced pluripotent cell-derived neurons were shown to have decr

120 switches address major safety concerns with pluripotent cell-derived therapies.

121 Pluripotent cells develop within the inner cell mass of

122 Characterization of a human pluripotent cell differentiation protocol recapitulating

123 ighting gene expression changes during human pluripotent cell differentiation.

124 In pluripotent cells, divergent lncRNAs regulate the transc

125 y developmental event during which embryonic pluripotent cells diversify into lineage-specific precur

126 neurons made from PD patient-derived induced pluripotent cells, dramatically reduced LRRK2-dependent

127 ces of neighbour exchange within cultures of pluripotent cells during differentiation.

128 E-1 (L1) retrotransposons, which mobilize in pluripotent cells early in development.

129 Pluripotent cells emerge as a naive founder population i

130 pecification occurs either by induction from pluripotent cells (epigenesis) or by a cell-autonomous m

131 ficient to drive robust neural commitment in pluripotent cells, even under non-permissive conditions.

132 preimplantation embryonic lethality because pluripotent cells fail to form and all cells differentia

133 se embryonic stem cells (ESCs) and defined a pluripotent cell fate (PCF) gene signature associated wi

134 of stem cell microenvironments that regulate pluripotent cell fate decisions and morphogenesis.

135 richardii, the WUS pro-orthologue marks the pluripotent cell fate of immediate descendants of the ro

136 cells (ESCs) provide an unlimited supply of pluripotent cells for articular cartilage tissue enginee

137 human blood cells and the potential of these pluripotent cells for disease modeling.

138 In addition, the use of pluripotent cells for drug screening could enable routin

139 prior to and independently of Cdh1 to prime pluripotent cells for mesoderm differentiation, thus hel

140 These conditions shield pluripotent cells from differentiation-inducing stimuli.

141 CX43) gap junction communication in cultured pluripotent cells from human dental follicles (hDFC).

142 ERK signalling, which promotes exit of naive pluripotent cells from self-renewal, does not prevent JA

143 Pluripotent cells from the early stages of embryonic dev

144 In culture, the ability of pluripotent cells from the embryo to respond to the FGF

145 Pluripotent cells generated from patients with T1D would

146 mine the trajectories connecting somatic and pluripotent cells, genetic and chemical methodologies fo

147 Previous reports have shown that naive pluripotent cells grown in the presence of 2i are charac

148 fects in a dataset profiling differentiating pluripotent cells (GSE32923) and another from human brai

149 that can restore muscle function from human pluripotent cells has not been achieved.

150 Recently, methods to derive ECs from pluripotent cells have extended the scientific range of

151 The recent derivation of human induced pluripotent cells (hiPSCs) provides a potential supply o

152 for precise genome editing in human-induced pluripotent cells (hiPSCs) will enable sophisticated gen

153 d the concept of co-culture of human induced pluripotent cells (hiPSCs) with various types of support

154 (NuRD) is required for lineage commitment of pluripotent cells; however, the mechanism through which

155 ly embryonic-lethal due to the abrogation of pluripotent cells in blastocysts.

156 that geminin is present in G1 phase of mouse pluripotent cells in contrast to somatic cells, where an

157 oincides with loss of epiblast pluripotency, pluripotent cells in development and in vitro can adopt

158 Nanog orthologs supported self-renewal of pluripotent cells in the absence of leukemia inhibitory

159 Thus, PGCs can give rise to pluripotent cells in the course of the developmental cyc

160 key role in choreographing the responses of pluripotent cells in the early embryo to the signals tha

161 Its inhibition lowers the percentage of pluripotent cells in the early mouse embryo and signific

162 Pluripotent cells in the embryo can generate all cell ty

163 ed-specific, proteins were also expressed by pluripotent cells in the human preimplantation embryo.

164 Pluripotent cells in the inner cell mass (ICM) are the d

165 curs during differentiation of Dnmt3a(W326R) pluripotent cells in vitro, and is also evident in Dnmt3

166 mplications for the generation of HSPCs from pluripotent cells in vitro.

167 iew recent insights into the nature of human pluripotent cells in vivo, obtained by the deep sequenci

168 These inhibitors generate human pluripotent cells in which transcription factors associa

169 The process by which pluripotent cells incorporate into host embryos is of in

170 The ability to differentiate pluripotent cells into anterior foregut endoderm (AFE) d

171 ial for driving the differentiation of human pluripotent cells into cell types useful for clinical ap

172 tively amplified upon differentiation of the pluripotent cells into disease-relevant lineages.

173 We differentiated pluripotent cells into either cortical or olfactory plac

174 fibroblast growth factor (FGF) drives naive pluripotent cells into extraembryonic lineages before im

175 upport a role for Wnts in differentiation of pluripotent cells into profibrotic fibroblasts and the p

176 ereby allowing for functional engraftment of pluripotent cells into regenerating tissue.

177 ssue or neural cultures derived from induced pluripotent cells (iPS), in conjunction with transcripto

178 Knockdown of SETDB1 in PWS-specific induced pluripotent cells (iPSCs) causes a decrease in the accum

179 Using induced pluripotent cells (iPSCs) from patients with mutation in

180 Generation of patient-specific induced pluripotent cells (iPSCs) holds great promise for regene

181 uman embryonic stem cells (ESCs) and induced pluripotent cells (iPSCs) into neurons are often cumbers

182 Reprogramming somatic cells into induced-pluripotent cells (iPSCs) provides new access to all som

183 iving lung progenitors from patient-specific pluripotent cells is a key step in producing differentia

184 Targeted genetic engineering of human pluripotent cells is a prerequisite for exploiting their

185 generation of differentiated DA neurons from pluripotent cells is a prerequisite for the use of hiPSC

186 Signal attenuation in pluripotent cells is observed even at saturating doses,

187 The conversion of somatic cells into pluripotent cells is transforming the way diseases are r

188 Additionally, quiescent pluripotent cells lacking Mga are lost during embryonic

189 n vitro and in vivo differentiation of human pluripotent cells, likely through defects in the silenci

190 oduct, the HERVK accessory protein Rec, in a pluripotent cell line is sufficient to increase IFITM1 l

191 scle that is potentially applicable to other pluripotent cell lines and to generating other forms of

192 epiblast stem cells (EpiSCs), self-renewing pluripotent cell lines equivalent to the postimplantatio

193 Recently, haploid pluripotent cell lines from medaka fish (Oryzias latipes

194 strate the derivation of robustly expandable pluripotent cell lines from STAP cells.

195 The peptides supported growth of eight pluripotent cell lines on a variety of scaffolds.

196 of both enzymes in tandem results in viable, pluripotent cell lines with distinct effects on the DNA

197 aled 23 distinguishing candidate genes among pluripotent cell lines with divergent cardiogenic potent

198 ranscriptional and epigenetic comparisons of pluripotent cell lines, explaining some of the previousl

199 ubstantial variation has been reported among pluripotent cell lines, which could affect their utility

200 cells (EGCs) represent two classic types of pluripotent cell lines, yet their molecular equivalence

201 euroepithelial-like stem cells (lt-NES) from pluripotent cell lines.

202 quick and comprehensive characterization of pluripotent cell lines.

203 NT2 cell population density; levels of Oct4 (pluripotent cell marker) and HCMV genome penetration are

204 e the level of HCMV genomes in nuclei, Oct4 (pluripotent cell marker), or hDaxx (cellular repressor o

205 Resultant iPSC clones expressed pluripotent cell markers and generated teratomas.

206 that vector silencing follows acquisition of pluripotent cell markers.

207 H3K4me2 during formation of the intermediate pluripotent cell mass known as callus derived from Arabi

208 f Arabidopsis in vitro regeneration, where a pluripotent cell mass termed callus is induced.

209 activating EMT, and that the Nanog marker of pluripotent cells may act as the primary transcription f

210 bryos and suggest that a chimera assay using pluripotent cells may not be feasible.

211 the insights into telomere end protection in pluripotent cells mean for the t-loop model of end prote

212 Prematurely slowing MCM loading in pluripotent cells not only lengthens G1 but also acceler

213 rom a specified germ cell to a population of pluripotent cells occurs rapidly following fertilization

214 omplex vertebrate nervous system begins when pluripotent cells of the early embryo are directed to ac

215 ssential for formation of the totipotent and pluripotent cells of the early embryo.

216 through regulation of the polyamine pool in pluripotent cells of the embryo, whether they are in a p

217 transcription factor Mga is expressed in the pluripotent cells of the inner cell mass (ICM) and epibl

218 Both lin28a and lin28b are expressed in pluripotent cells of the Xenopus embryo and are enriched

219 Human trisomy 21 pluripotent cells of various origins, human embryonic st

220 factors to reprogram somatic cells to become pluripotent cells, offers a significant technical simpli

221 icient for neural induction, Tbx3-expressing pluripotent cells only form retina in the context of the

222 Whether regeneration is accomplished by pluripotent cells or by the collective activity of multi

223 the cells retained spectroscopic features of pluripotent cells or developed spectroscopic features su

224 n genomes due to their ability to amplify in pluripotent cells or developing germ cells.

225 The reprogramming of adult cells into pluripotent cells or directly into alternative adult cel

226 analysed and their silencing in germ cells, pluripotent cells or somatic cells remains poorly unders

227 nown whether there are additional classes of pluripotent cells, or what the spectrum of reprogrammed

228 scription factors that maintain an important pluripotent cell population called the shoot apical meri

229 d that the Msx1-expressing cells represent a pluripotent cell population for the regenerating digit.

230 rived from the blastema, an undifferentiated pluripotent cell population thought to be derived from m

231 minates in the establishment of two distinct pluripotent cell populations: the shoot apical meristem

232 Pluripotent cells possess the ability to differentiate i

233 sient downregulation of Nanog in a subset of pluripotent cells predisposes them toward differentiatio

234 During mouse embryonic development, pluripotent cells rapidly divide and diversify, yet the

235 d proliferative characteristics of embryonic pluripotent cells, reduces expression of pluripotency fa

236 re of embryonic development, but the role of pluripotent cell regulation in somatic tissue regenerati

237 argeted single-copy genomic integration into pluripotent cells, reporter assays and flow cytometry ar

238 Pluripotent cells represent a powerful tool for tissue r

239 er specification of definitive endoderm from pluripotent cells results in a highly enriched AFE popul

240 mming and the pooled selection of polyclonal pluripotent cells results in high-quality, stable iPSCs.

241 d female monkey ICMs indicating that ex vivo pluripotent cells retain XaXa.

242 work and will enhance our ability to control pluripotent cell self-renewal and differentiation.

243 in histone acetylation on cardiomyocyte and pluripotent cell-specific gene promoters.

244 scription factors, DNA methylation status at pluripotent cell-specific genes, and the capacity to dif

245 The latter also determines the pluripotent cell state, that is, naive or primed.

246 n can also promote reversion back to a naive pluripotent cell state.

247 s the possibility of transitioning through a pluripotent cell state.

248 entifies Srrt as a molecular guardian of the pluripotent cell state.

249 e, neither class of contacts was observed in pluripotent cells, suggesting that lineage-specific chro

250 s suggest a mechanism whereby Mga influences pluripotent cell survival through regulation of the poly

251 (pESCs) and bi-parental ESCs, establishing a pluripotent cell system of distinct parental backgrounds

252 In pluripotent cells, TDP-43 represses the formation of par

253 Lin28, can reprogram somatic cells back into pluripotent cells, termed induced pluripotent stem cells

254 ed, exhibiting lower nucleosome occupancy in pluripotent cells than in somatic cells.

255 thylation was slightly more prevalent in the pluripotent cells than in the fibroblasts.

256 s differentiation and enable self-renewal of pluripotent cells that are ex vivo counterparts of naive

257 ells (hiPSCs) provides a potential supply of pluripotent cells that avoid immune rejection and could

258 The ability to reprogram somatic cells into pluripotent cells that can be differentiated in vitro pr

259 Mesenchymal stem cells (MSCs) are pluripotent cells that can promote expansion of immune r

260 During early mammalian development, as the pluripotent cells that give rise to all of the tissues o

261 Human embryonic stem cells (hESCs) are pluripotent cells that have indefinite replicative poten

262 These 3D regulatory maps of human pluripotent cells therefore provide a foundation for fut

263 PRC2-bound elements function as silencers in pluripotent cells, they can transition into active tissu

264 by triggering genetic variation in germ and pluripotent cells through mutation followed by natural s

265 studies have aimed to convert cultured human pluripotent cells to a naive state, but it remains uncle

266 t, lineage-specific differentiation of human pluripotent cells to a NCSC fate.

267 of Tbx3 and Pax6 is sufficient to determine pluripotent cells to a retinal lineage.

268 uently, Foxd3 needs to be silenced in primed pluripotent cells to allow re-activation of relevant gen

269 early development, extrinsic triggers prompt pluripotent cells to begin the process of differentiatio

270 ic biology underlying the differentiation of pluripotent cells to cardiac lineages and describe curre

271 ellite cells and directed differentiation of pluripotent cells to mature skeletal muscle have proved

272 nds to achieve efficient conversion of human pluripotent cells to NCSCs in ~15 d.

273 factors that would be sufficient to instruct pluripotent cells to organize the embryo.

274 f7l1 as a unique factor that is necessary in pluripotent cells to prepare them for lineage specificat

275 ly development is governed by the ability of pluripotent cells to retain the full range of developmen

276 essary for a rapid switch in the response of pluripotent cells to Wnt/beta-catenin stimulation, from

277 imary human cells, including multipotent and pluripotent cells, to uncover both the underlying mechan

278 method for directed differentiation of human pluripotent cells toward neural crest stem cells has yet

279 lar mechanisms found in germ cells and other pluripotent cell types and identify genetic regulators o

280 Human embryonic stem cells (hESCs) are pluripotent cell types derived from the inner cell mass

281 nocytic stem cells in the hair follicle, and pluripotent cell types from the hair follicle and papill

282 Differences between pluripotent cell types were not observed in carbohydrate

283 lled stem cells, even though they range from pluripotent cells-typified by embryonic stem cells, whic

284 During embryonic development, uncommitted pluripotent cells undergo progressive epigenetic changes

285 e 3D chromatin landscape of naive and primed pluripotent cells, unveiling common features as well as

286 efficient targeting of three genes in human pluripotent cells using zinc-finger nuclease (ZFN)-media

287 x: How is cell-cycle progression possible in pluripotent cells when oscillations of key regulatory pr

288 Pluripotent cells, when fused with somatic cells, have t

289 ligase III, SSrp1, Xrcc-6/Ku70, and Parp2 in pluripotent cells, which decreased during the differenti

290 s transition coincides with the formation of pluripotent cells, which in mammals can be used to gener

291 pically upregulated, both in male and female pluripotent cells, while Tsix expression aberrantly pers

292 mbryos, where EPHA receptors are enriched in pluripotent cells whilst surrounding lineage-specified t

293 In clinical practice, most pluripotent cells will be differentiated into useful the

294 Studies have shown that pluripotent cells with abnormal karyotypes may grow fast

295 is possible to apply genome editing to human pluripotent cells with minimal impact on genomic mutatio

296 e site-specific genome modification in human pluripotent cells with similar efficiency and precision

297 Pluripotent cells within embryonal carcinoma (EC) can di

298 approach is accomplished directly from human pluripotent cells without the need for coculture on feed

299 generate hematopoietic stem cells from human pluripotent cells would enable many biomedical applicati

300 In vitro differentiation of pluripotent cells yields mostly alpha- and polyhormonal